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Multiple endocrine neoplasia type 2 (MEN2) syndromes are 
autosomally dominant clinical associations characterised by a 
number of tumours, including medullary thyroid carcinoma 
(MTC), phaeochromocytoma, thyroid C-cell hyperplasia (CCH), 
parathyroid tumours (MEN2A) and ganglioneuroma of the gastro-
intestinal tract (MEN2B). The common factor in the MEN2 
syndromes is MTC, a poorly differentiated thyroid malignancy 
that represents 3 - 10% of thyroid tumours1,2 but is hereditary in 
20 - 30% of cases. 
MTC (and other thyroid tumours) have been shown to be 
genetically linked to mutations in the RET (REarranged during 
Transfection) proto-oncogene (situated at 10q223,4), which plays 
a pivotal role in at least four clinical syndromes (MEN2A and 
MEN2B, familial medullary thyroid carcinoma (FMTC) and 
Hirschsprung’s disease (HSCR)) in a unique ‘switch on, switch 
off ’ manner.5 RET gene variations are  present in more than 50% 
of MTC cases  as well as a significant number of papillary thyroid 
carcinomas (chromosomal inversions or translocations (RET/
PTC).6 
Inheritance is important, and the risk to family members 
appears to be particularly high in MEN2. Patients with genetic 
mutations involving the cysteine radicals of the gene account for 
92 - 95% of those who later develop MTC.7,8 Children of families 
with MTC and the MEN2 syndromes have been reported to 
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Summary 
The RET proto-oncogene (REarranged during Transfection; 
RET) plays an important role in the causation of many thyroid 
tumours. Germline RET proto-oncogene missense mutations 
have been clearly linked to medullary thyroid carcinoma 
(MTC) and the inherited cancer syndrome multiple endocrine 
neoplasia type 2 (MEN2A, MEN2B). 
Methods. We investigated a cohort of MEN2-related 
patients referred to Tygerberg Hospital, W Cape (2003 - 
2009). The study cohort was divided into three groups based 
on pathology (viz. MEN/MTC, phaeochromocytoma, and a 
miscellaneous group of MEN pathologies). Families with 
identified high-risk factors were recalled. Serum calcitonin 
levels were monitored where indicated. 
DNA was extracted from whole blood by standard 
techniques and polymerase chain reaction (PCR) products 
screened for RET gene variations by heteroduplex single-
strand duplication techniques (heteroduplex single-strand 
conformation polymorphism analysis) being validated with 
automated sequencing techniques showing conformational 
variants in acrylamide gel.
Results. We screened 40 persons, male/female ratio 
1:1.5. Three ethnic groups were represented (white (12), 
black (11) and mixed race (17)).  Nine were index MTC 
cases, 5 phaeochromocytoma, 3 Hirschsprung’s disease-
MEN associations and 2 miscellaneous (1 neuroblastoma, 
1 intestinal neuronal dysplasia), while 1 fell into the MEN2B 
category. The remaining 19 were unaffected relatives 
screened for carrier status, among whom a familial recurrence 
was observed in 7. 
On genetic testing, an RET point mutation at the high-
risk 634 cysteine allele was identified in 11 cases. A further 
cysteine radical mutation at the 620 position was related 
to MEN2 in 3 families plus 1 other family referred from 
elsewhere. Other less-recognised gene variations were 
detected throughout the RET gene in 70% of cases and 
included the 691 position on codon 11 (11 cases); the 432 
position (4 cases, 1 homozygous) intronic mutations on exon 
4 (1 case); and an IVS19-37G/C and a D1017N variation in 
exon 19 in 2 MEN families. 
Fifteen MTC patients have had thyroidectomies, of which 
2 were prophylactic (C-cell hyperplasia; early occult MTC). A 
further 3 are awaiting prophylactic surgery. 
Conclusion. RET gene mutation carries a risk of MEN2 
and MTC in all ethnic groups in South Africa. Prophylactic 
surgery may prevent MTC, so genetic screening is important 
to identify and treat high-risk patients. 
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develop early metastatic tumours even before the age of 5 years.9 
In  tumours associated with mutations at the 918 allele (MEN2B), 
early aggressive behaviour with distant metastatic spread is 
typical10 and  cases of inherited MTC have been reported as early 
as 2 months of age.11 These patients may develop the premalignant 
CCH even earlier,12 and early lymph node metastases may occur.13 
MTC is a particularly chemo/radio-resistant tumour (spreading 
mostly via the lymphatic system) often resulting in death, so 
prophylactic removal of the target organ before the onset of 
malignancy remains a surgical goal.6 Research over the past decade 
has clearly shown that RET gene evaluation is of great value 
in familial screening and evaluating risk in familial cases, thus 
determining the timing of prophylactic surgical intervention.14
As there is some evidence that oncogenic RET mutations may 
vary between specific ethnic groups,15,16 evaluation of the diverse 
South African population is of specific local interest. 
The aim of this study was to evaluate the profile of RET in 
MEN2 families with special attention to the risk to children, 
and to assess risk and determine treatment protocols for their 
management.  
Methods
Subjects 
We investigated a cohort of MEN2-related patients referred 
to Tygerberg Hospital (2003 - 2009). The study cohort was 
divided into three groups based on pathology (viz. MEN/MTC, 
phaeochromocytoma, and a miscellaneous group of MEN 
pathologies). Families with identified high-risk factors were 
recalled.  
Unaffected family members of patients with high-risk gene 
variations were recalled for genetic testing and genetic counselling.
Serum calcitonin and other biochemical variables were analysed 
where possible.
Patients with HSCR-MEN co-segregation were identified as part 
of a separate study of RET in HSCR.17 
DNA analysis
DNA extraction was performed on colonic tissue samples and 
whole blood using standard techniques. Polymerase chain 
reaction (PCR) amplification of the 21 exons of the RET gene 
was performed using intronic primers.18 The PCR products 
were subjected to heteroduplex single-strand conformation 
polymorphism analysis19 and resolved in a polyacrylamide (PAA) 
gel supplemented with 7.5% urea (consisting of 4.5 g urea, 18 
ml 5XTBE, 24 ml dH2O, 18 ml PAA (1% C of a 40% stock), 600 
µl APS (10%) and 60 µl TEMED) at 4oC (350 V) for 18 hours. 
The DNA fragments were also electrophoresed in a 10% PAA gel 
supplemented with 5% glycerol (consisting of 3 ml glycerol, 6 ml 
5XTBE, 36 ml dH2O, 15 ml PAA (1% C of a 40% stock), 800 µl 
APS (10%) and 80 µl TEMED) at room temperature (300 V). The 
DNA fragments were stained in ethidium bromide and visualised 
by ultraviolet light transillumination. Semi-automated DNA 
sequencing (ABI 310 PRISM) was performed on PCR products 
demonstrating mobility or conformational variants on the PAA 
gels.
Controls 
An additional group of unaffected controls (N=60) were recruited 
from the normal population for comparison of the genetic profile 
of the ethnic population groups represented in the study (20 
patients per ethnic group, i.e. 20 white, 20 black and 20 coloured 
patients). Unaffected family members of patients with high-risk 
gene variations were recalled for genetic testing and genetic 
counselling.
Ethical permission
The research project was approved by the research committee at 
Stellenbosch University (2001/C019) and conducted according 
to the accepted ethical codes and guidelines, as outlined in the 
declaration of Helsinki
Results
Forty persons were screened (male/female ratio 1:1.5). Their 
ages ranged from newborn to 54 years, and 7 were children 
aged <13 years. All ethnic groups were represented (white 
12, black 11, coloured 17). There were 9 index MTC cases, 5 
phaeochromocytoma, 3 HSCR-MEN associations and 2 
miscellaneous (1 neuroblastoma, 1 intestinal neuronal dysplasia); 
1 patient fell into the MEN2B category. The remaining 19 were 
unaffected relatives screened for carrier status, among whom a 
familial recurrence was observed in 7 (37%). Serum calcitonin 
levels were raised in 19 of the 21 affected patients. In 2 patients 
early MTC was not associated with raised calcitonin levels.
On genetic testing, an RET point mutation was identified in 21 
of the 40 patients (52.5%) (Table I). The genetic variation occurred 
at the high-risk 634 cysteine allele in 11 of these (52%). A further 
cysteine radical mutation at the 620 position was related to MEN2 
in 3 families, plus 1 other unique family referred from elsewhere, 
in which MEN and HSCR co-existed.20 Other less-recognised gene 
variations were detected throughout the RET gene in 70% of cases 
and included the 691 position on codon 11 (11 cases); the 432 
position (4 cases, 1 homozygous); intronic mutations on exon 4 (1 
case); and an IVS19-37G/C and a D1017N variation in exon 19 in 
2 MEN families (Table I). Additional polymorphisms of the gene 
occurred in both patients and controls (Table II).
Fifteen patients underwent surgical removal of the thyroid gland 
(total thyroidectomy), including 3 prophylactic thyroidectomies 
in gene-positive family members. In one 6-year-old, CCH (a 
premalignant stage12) (Fig. 1) was identified along with a twice-
normal serum calcitonin level. In another 2, early occult MTC was 
detected (serum calcitonin 3 times normal in 1) (Fig. 2). A further 
2 are awaiting prophylactic surgery. 
A cysteine radical mutation (C620R and C620W) was related to 
MEN2 in 3 families, with proven MTC in recurrent patients in 2 
and suspected in the other. In addition, it was a major factor in a 
unique family referred from elsewhere in which MEN and HSCR 
co-existed.
Discussion
This study confirms the association of RET gene mutation with 
cancer risk in MEN2 and MTC families in all ethnic groups in 
the diverse South African population. As MTC is a particularly 
chemo/radio-resistant tumour, spreading mostly via the lymphatic 
system and often resulting in death, the major benefit of RET 
genetic testing lies in the early preclinical identification of carriers 
of the RET mutation and timely prophylactic thyroidectomy,6 as 
carried out in this study. 
Activating mutations of RET appear to be of the order of 
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TABLE I. POTENTIAL DISEASE-CAUSING MUTATIONS IDENTIFIED IN THE RET PROTO-ONCOGENE IN MEN2 
PATIENTS (N=21/40) 
Exon/Intron Mutation
Nucleotide 
change
Effect on coding 
sequence
No. of 
patients
Gender/ethnic 
group Diagnosis
4 IVS4-18G/A Splice acceptor 1 WM MEN2B
10 *C620W TGC→TGG Missense 2 CM/CF HSCR-MEN2
11 *C634S TGC→AGC Missense 8 BF/BF/BF MEN2A
11 *C634Y TGC→TAC Missense 2 WF MEN2A
11 *C634R TGC→CGC Missense 2 CF/CF MEN2A
12 A750P GCA→CCA Missense 2 CF/CF MEN2A
13 D771N GAC→AAC Missense 1 WF FMTC
18 M1009V ATG→GTG Missense 1 WF FMTC
19 D1017N GAC→AAC Missense 1 CF FMTC
19 V1041G GTG→GGG Missense 1 BF MEN2A
20 IVS19-37G/C Splice acceptor 1 CM MTC carrier
*Related to cysteine radicals on RET gene.
Ethnic grouping: W (M/F) = white; C (M/F) = coloured (mixed ancestry); B (M/F) = black African.
TABLE II. POLYMORPHISMS IDENTIFIED IN THE RET PROTO-ONCOGENE IN MEN2 PATIENTS AND 
CONTROLS
Exon/intron Codon Nucleotide change
                                   Allele frequency*
BC (N=60) CC (N=58) WC (N=50) MTC patients
2 A45 GCG→GCA 0.06 0.31 0.5 (25) 0.12
7 A432 GCG→GCA 0.0 0.12 0.06 0.1
13 L769 CTT→CTG 0.0 0.20 0.18 -
15 S904 TCC→TCG 0.25 0.41 0.06 -
*Allele frequency of polymorphic allele denoted.
BC = black control group; CC = coloured control group; WC = white control group.
Fig. 1. Calcitonin immunostain of prophylactically excised thy-
roid gland of a 6-year-old 634 carrier, showing increased calci-
tonin activity and C-cell hyperplasia (×160).
Fig. 2. Medullary thyroid carcinoma in the 36-year-old 
mother of a Hirschsprung’s disease patient with a C620 point 
mutation. 
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1:500 000 in the general population.21 Consistent associations 
exist between RET genotype and phenotype, and the ‘gain of 
function’ variations associated with MEN2 can be divided into two 
main groups (viz. those affecting one of the six cysteine radicals 
(609, 611, 618, 620, 630 and 634 positions) (MEN2A) and those 
affecting the tyrosine kinase domain22 (MEN2B)). MTC in MEN2B 
is associated with a point mutation (methionine→threonine) in 
exon 16(M918/T) of the RET proto-oncogene in 95% of cases.23,24 
Genetic variants at amino acid positions 634 (MEN2a) and 
918 (MEN2b) carry a particularly high-risk profile of MTC in 
offspring when compared with others.25,26 Other MEN2 tumours 
(e.g. phaeochromocytoma) may also be related to RET but usually 
occur later in life.27 
RET proto-oncogene testing has been shown to be vastly 
superior to measurement of calcitonin levels in identifying 
preclinical MTC cases, with a specificity approaching 95 - 100%.28 
Genetic screening is extremely sensitive in MEN2 syndromes, 
and children of MTC families who are carriers of mutant genes 
are at risk and may be identified by detection of the germline 
mutation in the RET proto-oncogene. These are particularly 
related to RET cysteine mutations in exons 10, 11, 13 and 16, but 
other RET variations also appear to carry risk. In this study, 2 
family members with high-risk RET mutations and an early MTC 
detected at thyroidectomy had normal serum calcitonin levels, 
demonstrating the value of RET gene screening in diagnosis.
A further interesting phenomenon is the relatively uncommon 
co-segregation of HSCR and MEN2 in the same patient,20,29,30 
i.e. involving both gain and loss of gene function. This was 
encountered in 2 families in South Africa and has been reported 
elsewhere.20
The high frequency with which the C620 RET mutation occurs 
in HSCR-MEN patients suggests the concept of the so-called 
‘Janus gene’ mutation in this position, which like the Roman god 
of transition can face in two directions (i.e. activation (MEN/
MTC) and inactivation (HSCR)).20
In 2007 Machens and Dralle28 stratified MTC risk into three 
categories according to mutation-related aggressiveness, giving 
rise to a concept of ‘codon-directed’ timing of surgery. One long-
term follow-up study of 46 RET gene carriers categorised the risk 
to children and young adults (aged 4 - 21 years) into low-risk 
(level 1) and intermediate- to high-risk (level 2) mutations.31 Level 
1 mutations appeared to be associated with variations in codons 
790, 791, 804 and 891 and had a high rate of cure. In contrast, 5 
(14%) of the 35 level 2 patients (mutations of codons 618, 620, 
630 and 634) had ongoing disease. On long-term follow-up 
(mean 6.4 years), 2 of those with 634 mutations developed other 
MEN manifestations (viz. hyperparathyroidism and bilateral 
phaeochromocytoma). This latter risk would probably increase 
with time, and long-term follow-up is necessary. Level 3 mutations 
include those at positions 883 and 918. 
Patients with phenotypic features resembling MEN2B always 
require genetic testing even if the family history is negative, 
because of the high incidence of spontaneous mutations 
(approximately 50%)32,33 and the early onset of MTC. Offspring of 
people with MEN2B-related MTC have a particularly high risk of 
an early aggressive carcinoma, the youngest reported case being at 
2 months of age.11
The RET proto-oncogene has been shown to have a significant 
role in cancer treatment and prevention. Although many of the 
tumours only occur later in life,6 surgical decision making is 
required in the childhood years, which then raises a number 
of points for discussion. The first of these is the question of 
timing of codon-directed prophylactic thyroid surgery, the second 
the timing and extent of genetic screening, and the third the 
nature of patient follow-up and the subsequent risk of other 
MEN-related tumours, which has to be accompanied by adequate 
genetic counselling. It is recommended that testing should be 
carried out before 1 year of age in children (especially in families 
with 883/918 codon mutations) and before 5 years in MEN2A 
families (especially with mutations of codons 611, 618, 620 and 
634). The high incidence of early aggressive tumours associated 
with MEN2B11,34 warrants an aggressive surgical approach with 
early prophylactic thyroidectomy in gene carriers (<1 year).6,13 
Total thyroidectomy is recommended, with central lymph node 
dissection being added in cases of MEN2B.6
In addition to its role in MTC, tyrosine kinase activity 
upregulation has been demonstrated in other thyroid tumours by 
the RET/PTC fusion gene in papillary thyroid carcinoma.35 After 
the Chernobyl disaster (ionising radiation), papillary thyroid 
tumours in children showed a high prevalence of RET fusion gene 
rearrangements, with at least 11 of these being described (the 
majority being an RET/PTC3 rearrangement).36 
The mechanisms by which the RET proto-oncogene variation 
results in gene activation and thus causes thyroid cancer is not yet 
fully clear. The ‘gain of function’ variations in the cysteine-rich 
extracellular domain of RET probably activate RET by inducing 
aberrant disulfide-linked homodimerisation.24,37,38 In addition, 
RET extracellular domain mutations may result in the unfolding 
of RET. In MEN2B the 918 mutation alters the substrate specificity 
of RET tyrosine kinase and induces a different set of signalling 
pathways to those in  MEN2A. Y1062 (a critical regulator of Ret9 
signalling) appears to be an important location on the gene.39 The 
downstream effects of RET activation are not fully clear, but RET 
binds to the glial-derived neurotrophic factor (GDNF) co-receptor 
which then activates various signalling pathways (e.g. RAS/
extracellular signal-regulated kinase (ERK), phosphatidylinositol 
3-kinase (PI3K)/AKT (serine/threonine protein kinase AKT 
pathway), p38 mitogen-activated protein kinase (MAPK) and 
c-Jun N-terminal kinase (JNK) pathways40) via its GDNF-family 
co-receptors (GFR alpha (GDNF-family receptor-alpha), etc.). 
Approximately 50% of MTC can therefore be genetically related 
to an RET proto-oncogene mutation,6 with point mutations mostly 
in high-risk areas of the gene. Prophylactic surgery appears to 
prevent the cancer if it is in the CCH pre-cancerous phase; it 
remains the ultimate  surgical goal,28,41 and should precede the 
development of lymph node metastases.  Pre-operative serum 
calcitonin measurement is important for follow-up. Although 
there is some debate as to the extent of the surgery, it is 
accepted that  total thyroidectomy with bilateral cervico-central 
lymphadenectomy is adequate  ‘prophylactic’ therapy.42 Revision 
surgery may entail cervico-lateral lymphadenectomy if the 
calcitonin levels remain elevated postoperatively, as widespread 
lymph node involvement may be present.43 
In addition to identifying patients at cancer risk, study of the 
RET proto-oncogene has more recently led to the development of 
novel molecular approaches to cancer therapy and clinical trials 
are currently being evaluated in patients with advanced disease.44
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Conclusion
RET gene mutation carries a risk of MEN2 and MTC in all ethnic 
groups in South Africa. Prophylactic surgery may prevent MTC, 
making genetic screening important in identifying and treating 
high-risk patients 
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